Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 2, 2015, Pages 156-162

  Conway, Richard ^a,b   Low, Candice ^c   Coughlan, Robert J ^a   O'Donnell, Martin J ^b   Carey, John J ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c Stroke and Hypertension Unit   (Ireland)

Author keywords

Drug induced liver injury; Hepatitis; Liver; Meta analysis; Methotrexate

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BRIAKINUMAB; CPH 82; CYCLOSPORIN A; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; IGURATIMOD; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; PAEONIFLORIN; PLACEBO; SALAZOSULFAPYRIDINE; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CROHN DISEASE; DEATH; DISEASE SEVERITY; DRUG SAFETY; HUMAN; HYPERTRANSAMINASEMIA; INFLAMMATORY BOWEL DISEASE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TREATMENT DURATION; DRUG-INDUCED LIVER INJURY; RISK;

DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RISK; RISK ASSESSMENT;

EID: 84941742496     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.05.003     Document Type: Article

References (57)

1. Sweetman S. (editor), Martindale: The complete drug reference. London: Pharmaceutical Press. 2005 [Accessed 13.09.14]. https://www.medicinescomplete.com/mc/martindale/current/search.htm?q=methotrexate&searchButton=+.
2. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
3. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
4. Khan Z.A., Tripathi R., Mishra B. Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 2012, 9:151-169.
5. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
6. West S.G. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997, 23:883-915.
7. Livertox®. Accessed [13.09.14]. 〈〉. http://livertox.nih.gov/Methotrexate.htm.
8. Amital H., Arnson Y., Chodick G., Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009, 48:1107-1110.
9. Tilling L., Townsend S., David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006, 26:55-62.
10. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
11. Rojas-Feria M., Castro M., Suárez E., Ampuero J., Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol 2013, 19:7327-7340.
12. Conway R., Low C., Coughlan R.J., O'Donnell M.J., Carey J.J. Methotrexate and lung disease in rheumatoid arthritis-a meta-analysis of randomized controlled trials. Arthritis Rheum 2014, 66:803-812.
13. The Cochrane Collaboration, Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre; 2011.
14. Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed 01.04.14.] Available from http://www.cochrane-handbook.org.
15. Dougados M., Kissel K., Conaghan P.G., Mola E.M., Schett G., Gerli R., et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014, 73:803-809.
16. Feagan B.G., McDonald J.W., Panaccione R., Enns R.A., Bernstein C.N., Ponich T.P., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn[U+05F3]s disease. Gastroenterology 2014, 146:681-688. e1.
17. Takeuchi T., Miyasaka N., Zang C., Alvarez D., Fletcher T., Wajdula J., et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol 2013, 23:623-633.
18. Chen L., Qi H., Jiang D., Wang R., Chen A., Yan Z., et al. The new use of an ancient remedy: a double-blinded randomized study on the treatment of rheumatoid arthritis. Am J Chin Med 2013, 41:263-280.
19. Chen X.X., Dai Q., Huang A.B., Wu H.X., Zhao D.B., Li X.F., et al. A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis. Clin Rheumatol 2013, 32:99-108.
20. Gottlieb A.B., Langley R.G., Strober B.E., Papp K.A., Klekotka P., Creamer K., et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012, 167:649-657.
21. Kingsley G.H., Kowalczyk A., Taylor H., Ibrahim F., Packham J.C., McHugh N.J., et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012, 51:1368-1377.
22. Reich K., Langley R.G., Papp K.A., Ortonne J.P., Unnebrink K., Kaul M., et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011, 365:1586-1596.
23. Ishaq M., Muhammad J.S., Hameed K., Mirza A.I. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Mod Rheumatol 2011, 21:375-380.
24. Keystone E., Genovese M.C., Klareskog L., Hsia E.C., Hall S., Miranda P.C., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010, 69:1129-1135.
25. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
26. Wei W., Zhang L.L., Xu J.H., Xiao F., Bao C.D., Ni L.Q., et al. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R180.
27. Emery P., Fleischmann R.M., Moreland L.W., Hsia E.C., Strusberg I., Durez P., et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009, 60:2272-2283.
28. Lu L.J., Bao C.D., Dai M., Teng J.L., Fan W., Du F., et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 2009, 61:979-987.
29. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12-19.
30. Hu D., Bao C., Chen S., Gu J., Li Z., Sun L., et al. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatol Int 2009, 29:297-303.
31. Zhang L.L., Wei W., Xiao F., Xu J.H., Bao C.D., Ni L.Q., et al. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:905-910.
32. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
33. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
34. Gerards A.H., Landewé R.B., Prins A.P., Bruyn G.A., Goei Thé H.S., Laan R.F., et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003, 62:291-296.
35. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001, 44:1984-1992.
36. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
37. Emery P., Breedveld F.C., Lemmel E.M., Kaltwasser J.P., Dawes P.T., Gömör B., et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
38. Lerndal T., Svensson B. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:316-320.
39. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999, 58:220-225.
40. Haagsma C.J., van Riel P.L., de Jong A.J., van de Putte L.B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997, 36:1082-1088.
41. Boers M., Verhoeven A.C., Markusse H.M., van de Laar M.A., Westhovens R., van Denderen J.C., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318.
42. Rau R., Herborn G., Menninger H., Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997, 36:345-352.
43. O'Dell J.R., Haire C.E., Erikson N., Drymalski W., Palmer W., Eckhoff P.J., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
44. Willkens R.F., Urowitz M.B., Stablein D.M., McKendry R.J., Berger R.G., Box J.H., et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992, 35:849-856.
45. Williams H.J., Ward J.R., Reading J.C., Brooks R.H., Clegg D.O., Skosey J.L., et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992, 35:259-269.
46. Weinblatt M.E., Kaplan H., Germain B.F., Merriman R.C., Solomon S.D., Wall B., et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990, 33:330-338.
47. Visser K., van der Heijde D.M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009, 27:1017-1025.
48. Curtis J.R., Beukelman T., Onofrei A., Cassell S., Greenberg J.D., Kavanaugh A., et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010, 69:43-47.
49. Dirven L., Klarenbeek N.B., van den Broek M., van Groenendael J.H., de Sonnaville P.B., Kerstens P.J., et al. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin Rheumatol 2013, 32:585-590.
50. Walker A.M., Funch D., Dreyer N.A., Tolman K.G., Kremer J.M., Alarcón G.S., et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993, 36:329-335.
51. Quintin E., Scoazec J.Y., Marotte H., Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010, 12:R143.
52. Bach N., Thung S.N., Schaffner F. The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 1998, 122:342-345.
53. Kaplan M.M., DeLellis R.A., Wolfe H.J. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997, 126:682-688.
54. Kaplan M.M., Bonder A., Ruthazer R., Bonis P.A. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010, 55:3207-3217.
55. Sokolove J., Strand V., Greenberg J.D., Curtis J.R., Kavanaugh A., Kremer J.M., et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:1612-1617.
56. Rossi R.E., Parisi I., Despott E.J., Burroughs A.K., O'Beirne J., Conte D., et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol 2014, 20:17352-17359.
57. Katchamart W., Trudeau J., Phumethum V., Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009, 68:1105-1112.